Rifai is focused on enhancing the overall lifestyle of its clients. The fun and creative packaging reinforces the idea that ...

Basis EHR established its first MVP release which subsequently made the system a preference among clinicians thus surpassing ...

Ipsen a confirmé ses objectifs financiers pour l’exercice 2025: Croissance des ventes totales du Groupe supérieure à 5,0%, à taux de change constant. Sur la base des taux de change en mars 2025, Ipsen ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Pursuant to the existing sales agreement entered into by the Company on December 22, 2022, ATM Shares may be sold from time to time at a sales price per ATM Share equal to prevailing USD market prices ...

Approving this extension of the maturity of the CB 2025 until September 17, 2025 is the first step in a larger holistic restructuring to provide the time required for its implementation, as announced ...

Conformément au contrat de vente existant conclu par la Société le 22 décembre 2022, les Actions ATM peuvent être vendues de temps en temps à un prix de vente par Action ATM égal aux prix du marché ...

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

Ipsen is confirming financial guidance for full-year 2025: Total sales growth greater than 5.0%, at constant currency. Based on the average level of exchange rates in March 2025, a limited effect on ...

Dr. Moses Haregewoyn leads Automated Health Systems, which uses technology and structured management to expand access to public healthcare for individuals, providers, and agencies. The company has ...

Rien ne garantit que les discussions avec Future Pak ou toute autre partie intéressée se traduiront par une opération. La Société tient à rassurer ses clients, ses employés et ses partenaires que, ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...